Stephen Hoge - 09 Nov 2023 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
President
Signature
/s/ James Dillon, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
09 Nov 2023
Net transactions value
-$18,084
Form type
4
Filing time
13 Nov 2023, 16:02:52 UTC
Previous filing
18 Sep 2023
Next filing
30 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise +522 +0.03% 1,574,709 09 Nov 2023 Direct F2
transaction MRNA Common Stock Sale $18,084 -263 -0.02% $68.76 1,574,446 10 Nov 2023 Direct F3
holding MRNA Common Stock 4,116 09 Nov 2023 By Valhalla, LLC
holding MRNA Common Stock 151,933 09 Nov 2023 By Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Restricted Stock Units Options Exercise $0 -522 -17% $0.000000 2,612 09 Nov 2023 Common Stock 522 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F2 Restricted stock units convert into common stock on a one-for-one basis.
F3 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F4 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.